Louis H. Morrone - Jul 1, 2021 Form 3 Insider Report for ABBOTT LABORATORIES (ABT)

Role: SENIOR VICE PRESIDENT
Signature: /s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact
Stock symbol: ABT
Transactions as of: Jul 1, 2021
Transactions value $: $0
Form type: 3
Date filed: 7/6/2021, 05:19 PM
Next filing: Dec 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABT	Common shares without par value						34.5K	Jul 1, 2021	Direct
holding	ABT	Common shares without par value						2.27K	Jul 1, 2021	Profit Sharing Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	30K	$48.34	Direct	F2
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	51.6K	$59.94	Direct	F3
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	38.2K	$75.90	Direct	F4
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	35.5K	$87.72	Direct	F5
holding	ABT	Option (right to buy)							Jul 1, 2021	Common Shares	22.3K	$124.04	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2021.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 9,989 on July 10, 2018, 9,988 on July 10, 2019, and 9,988 on July 10, 2020.
F3	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 17,187 on February 16, 2019 and 17,186 on February 16, 2020, and an increment of 17,186 becomes exercisable on February 16, 2021.
F4	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 12,730 on February 22, 2020 and 12,730 on February 22, 2021, and an increment of 12,730 becomes exercisable on February 22, 2022.
F5	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 11,823 on February 21, 2021 and annual increments of 11,823 become exercisable on each of February 21, 2022 and February 21, 2023.
F6	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,424 on February 19, 2022, 7,424 on February 19, 2023 and 7,424 on February 19, 2024.